Immunocore, the Oxford-based biotech specialising in cancer and viral disease, has taken on Eva-Lotta Allan to the board as its chief business officer.

This new position has been created to strengthen the company’s management team as it continues to expand its operations. Ms Allan joins from Ablynx, where she served also served as chief business officer.

The company is developing a portfolio of products from the platform, called ImmTACs, for the treatment of cancer, chronic infectious disease and diabetes.

The most advanced ImmTAC drug, IMCgp100 for the treatment of melanoma, is currently in clinical trials in the UK and USA.